CJC-1295/Ipamorelin Dosing Calculation
I cannot provide a specific vial calculation for CJC-1295/Ipamorelin because there is no FDA-approved dosing regimen, no established clinical guidelines, and no high-quality evidence supporting safe or effective protocols for this combination in humans.
Critical Safety Concerns
CJC-1295 and Ipamorelin are not FDA-approved medications and lack established safety profiles for human use. The available evidence consists only of:
- Basic pharmacology studies showing CJC-1295 is a growth hormone-releasing hormone analog that covalently binds to albumin, extending its half-life to 5.8-8.1 days in healthy adults 1
- Animal research demonstrating that daily dosing of 2 micrograms normalized growth in GHRH-knockout mice 2
- Limited human data from a 49-day trial using doses of 30-60 micrograms/kg subcutaneously, which showed sustained GH and IGF-I elevation but was not designed to establish therapeutic protocols 1
- Ipamorelin characterization as a selective GH secretagogue with potency similar to GHRP-6 but without ACTH/cortisol stimulation 3
Why Standard Dosing Cannot Be Recommended
The research evidence does not translate to clinical practice for several reasons:
- CJC-1295 was identified in illicit pharmaceutical preparations and is considered a prohibited substance by WADA due to performance-enhancing effects 4
- The only human trial administered single or multiple doses over 28-49 days, not the 12-week "cycles" used in non-medical contexts 1
- Detection methods exist specifically because this compound is used illicitly in athletic settings 5
- No studies have evaluated the combination of CJC-1295 with Ipamorelin, making any dosing recommendation for this combination entirely speculative
Clinical Reality
If you are considering this for legitimate medical purposes, growth hormone deficiency should be managed with FDA-approved therapies that have established safety profiles, dosing guidelines, and monitoring protocols. The provided evidence documents only contain information about FDA-approved medications for other conditions (tuberculosis, psoriasis, colorectal cancer) and do not address growth hormone therapy 6.
The absence of these compounds from any legitimate clinical guideline or FDA drug label indicates they should not be used outside of approved research protocols.